Lilly Asia Ventures
Stephen Lin, is a Partner with Lilly Asia Ventures (LAV). Prior to joining LAV, he most recently worked as BD at GlaxoSmithKline (Great China), covering M&A and product licensing. Prior to that, he managed the marketing of a core product at Merck Serono (China). In Sanjiu Medical & Pharmaceutical, he set up and headed the Strategic Development Department. Stephen holds Master of Science in Medicinal Chemistry and Bachelor in Pharmaceutical Chemistry, both from China Pharmaceutical University, and an M.B.A. degree from China Europe International Business School. He is also a Licensed Pharmacist in China.
This person is not in any offices
Lilly Asia Ventures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, they spun off and became an independent investment management company. As one of the earliest biomedical venture investors in China, they have been consistently investing in the region for over a decade, and have recently increased our footprint in the U.S. Our team of over 30 distinguished scientific, medical, investment, and operational professionals embrace a culture of integrity, entrepreneurship, and team work. Currently, they manage over $1.2 billion of committed capital.